Oppenheimer Asset Management Inc. Raises Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Oppenheimer Asset Management Inc. increased its holdings in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOMFree Report) by 11.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 54,114 shares of the company’s stock after acquiring an additional 5,598 shares during the period. Oppenheimer Asset Management Inc. owned approximately 0.31% of Global X Genomics & Biotechnology ETF worth $550,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Advisor Group Holdings Inc. boosted its holdings in Global X Genomics & Biotechnology ETF by 26.9% in the 4th quarter. Advisor Group Holdings Inc. now owns 3,916 shares of the company’s stock worth $49,000 after buying an additional 831 shares during the last quarter. Stifel Financial Corp boosted its holdings in Global X Genomics & Biotechnology ETF by 4.6% in the 1st quarter. Stifel Financial Corp now owns 25,039 shares of the company’s stock worth $308,000 after buying an additional 1,102 shares during the last quarter. Rockefeller Capital Management L.P. boosted its holdings in Global X Genomics & Biotechnology ETF by 19.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,200 shares of the company’s stock worth $116,000 after buying an additional 1,493 shares during the last quarter. Lido Advisors LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 0.6% in the 1st quarter. Lido Advisors LLC now owns 323,969 shares of the company’s stock worth $3,991,000 after buying an additional 1,886 shares during the last quarter. Finally, IFP Advisors Inc boosted its holdings in Global X Genomics & Biotechnology ETF by 121.0% in the 2nd quarter. IFP Advisors Inc now owns 3,521 shares of the company’s stock worth $53,000 after buying an additional 1,928 shares during the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Trading Up 1.0 %

GNOM stock opened at $11.21 on Friday. Global X Genomics & Biotechnology ETF has a 12-month low of $8.63 and a 12-month high of $13.42. The stock has a market cap of $92.26 million, a price-to-earnings ratio of -4.79 and a beta of 1.03. The business’s 50-day moving average is $11.18 and its 200 day moving average is $10.72.

Global X Genomics & Biotechnology ETF Company Profile

(Free Report)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.

See Also

Want to see what other hedge funds are holding GNOM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global X Genomics & Biotechnology ETF (NASDAQ:GNOMFree Report).

Institutional Ownership by Quarter for Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.